We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study.
- Authors
Alpuente, Alicia; Gallardo, Victor J.; Caronna, Edoardo; Torres‐Ferrús, Marta; Pozo‐Rosich, Patricia
- Abstract
Background and purpose: Monoclonal antibodies targeting CGRP or its receptor, anti‐CGRP mAbs, are proven to be effective treatments in migraine prevention. Real‐world evidence studies assessing their efficacy are scarce. Methods: Our objective was to assess the efficacy of anti‐CGRP mAbs in our clinical cohort resistant to onabotulinumtoxinA. We prospectively analyzed ≥50% response rate in patients who initiated treatment with anti‐CGRP mAbs and who were partial or nonresponders to onabotulinumtoxinA. Results: One hundred fifty‐five patients completed treatment with anti‐CGRP mAbs at 3 months of follow‐up. No statistically significant differences were found in ≥50% response in headache frequency in patients with prior onabotulinumtoxinA treatment partial or complete failure. Regarding dual therapy with onabotulinumtoxinA and anti‐CGRP mAbs, no statistically significant differences were found in ≥50% response in headache frequency between monotherapy or dual therapy. Conclusions: Patients with prior treatment failure or partial efficacy to onabotulinumtoxinA respond to anti‐CGRP mAbs. After 3 months, in our cohort, dual therapy does not seem to add more benefit than anti‐CGRP mAbs in monotherapy.
- Subjects
BOTULINUM A toxins; MONOCLONAL antibodies; EVIDENCE
- Publication
European Journal of Neurology, 2021, Vol 28, Issue 7, p2378
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/ene.14828